← All X4 Pharmaceuticals, INC filings

X4 Pharmaceuticals, INC 8-K filings

NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals Reports First Quarter 2024 Results and Provides Corporate Update
X4 Pharmaceuticals announced its first quarter 2024 financial results, highlighted by the U.S. launch of XOLREMDI for WHIM syndrome and upcoming clinical data presentations.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals' XOLREMDI Receives FDA Approval, Launches with Patient Support Program
X4 Pharmaceuticals announced FDA approval and commercial launch of XOLREMDI for WHIM syndrome, along with a patient support program and pricing details.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals Receives FDA Approval for XOLREMDI, First Treatment for WHIM Syndrome
X4 Pharmaceuticals announced FDA approval of XOLREMDI (mavorixafor) capsules, the first drug specifically indicated for patients with WHIM syndrome.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals Regains Nasdaq Compliance After Stock Price Rebounds
X4 Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for a sustained period.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals Posts Updated Corporate Presentation
X4 Pharmaceuticals has released an updated corporate presentation on its website, accessible through the investor relations section.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
8-K: X4 Pharmaceuticals Reports Full Year 2023 Results and Anticipates Key Milestones
X4 Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress towards potential FDA approval of mavorixafor for WHIM syndrome and the initiation of a Phase 3 trial for chronic neutropenia.